Education
About Us
Working with TipRanks
Follow Us
Rahul D. Ballal Insider Profile
4 Followers
Rahul D. Ballal, Director at Enliven Therapeutics, holds 7.99K shares in Agios Pharma (Ticker: AGIO), holds 22.34K shares in Enliven Therapeutics (Ticker: ELVN).
Profitable Transactions
2 out of 2 Profitable Transactions
Average Return
+18.20%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Rahul D. Ballal holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Sell
Date:Feb 22, 2023 - Feb 22, 2024
Return:+27.00%
The most profitable trade made by Rahul D. Ballal
Rahul D. Ballal's Trading History
Enliven Therapeutics
Oct 10, 2024
Director
Uninformative Buy
146.92K
$469.16K
Agios Pharma
Nov 12, 2024
Director
Uninformative Buy
519.80K
$258.78K
List of latest transactions for each holding click on a transaction to see Rahul D. Ballal's performance on stock
You May Also Like
Rahul D. Ballal insider profile FAQ
What is the percentage of profitable transactions made by Rahul D. Ballal?
The percentage of profitable transactions made by Rahul D. Ballal is 100%.
What is the average return per transaction made by Rahul D. Ballal?
The average return per transaction made by Rahul D. Ballal is 18.20%.
What stocks does Rahul D. Ballal hold?
Rahul D. Ballal holds: ELVN, AGIO stocks.
What was Rahul D. Ballal’s latest transaction?
Rahul D. Ballal latest transaction was an Uninformative Buy of $519.80K.
What was Rahul D. Ballal's most profitable transaction?
Rahul D. Ballal’s most profitable transaction was an Informative Sell of ELVN stock on February 22, 2023. The return on the trade was 27.00%.
What is Rahul D. Ballal's role in Enliven Therapeutics?
Rahul D. Ballal's role in Enliven Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.